Our Science – Shukla Website
Suneet Shukla, Ph.D.
He joined Laboratory of Cell Biology, NCI, NIH in 2004 as a postdoctoral fellow in Dr. Suresh V Ambudkar's group and continued his reserach on ABC drug transporters in multidrug resistant cancer cells. Currently, he is working as Staff Scientist in LCB, NCI, NIH.
Development of modulators/inhibitors for ABC transporters
In our efforts to screen and develop new inhibitors for the ABC transporters, we are exploring natural compounds for their inhibitory potential on ABC transporters. We have shown that curcumin isolated from turmeric powder, which is consumed daily as a spice in many countries and plumbagin, a napthoquinone from plant origin, inhibit the drug resistance mediated by drug transporters. We are also working on tyrosine kinase inhibitors for their inhibitory activity on ABC drug transporters. The newly developed tyrosine kinase inhibitor AMN107 (nilotinib) inhibits the tyrosine kinase activity of the BCR-ABL protein and is an effective, frontline therapy for chronic-phase CML. We have shown that it is a high affinity inhibitor of ABCG2 function. We are characterizing its inhibitory activity on other ABC transporters now. We demonstrate that these inhibitors block ABCG2-mediated drug resistance and may increase oral bioavailability of ABCG2 substrates. Another area of focus for the development of inhibitors is the compounds from Developmental Therapeutics Program (DTP) chemical libraries. Based on structural similarity hits, several compounds from, DTP were projected to be potential inhibitors, our group is involved in a joint effort to screen the potential inhibitors of ABC transporters using these compounds (This is an ongoing work in collaboration with Drs. Susan E Bates, Robert Robey, Heidi Bokesch, Kirk R Gustafson, Curtis Heinrich and Michael Dean, NCI, NIH).
This page was last updated on 6/20/2013.